Medimmune Limited

Zyngenia, Inc.

Astrazeneca Ab

The Feinstein Institutes for Medical Research

Zygenia, Inc.

Peter Kiener

Herren Wu

Anthony Coyle

Changshou Gao

David M Hilbert

William Dall'Acqua

Viktor Roschke

David William Lafleur

Ling-Ling An

Su-Yau Mao

Melissa Marie Damschroder

Ronald Herbst

Partha S Chowdhury

Christian B Allan

James F Young

Ricardo Cibotti

Jane Tian

Theresa O'Keefe

Shixin Qin

William Dall'acqua

Melissa Damschroder

David Lafleur

Michael Scott Kinch

Solomon Langermann

Kelly Carles-Kinch

Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.

Multivalent and monovalent multispecific complexes and their uses

The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.

Anti-IFNAR1 antibodies with reduced Fc ligand affinity

EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.

EGFR-binding modular recognition domains

Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.

Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides

The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Humanized anti-CD19 antibodies

The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.

Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

High affinity antibodies against HMGB1 and methods of use thereof

The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored IgE and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of IgE-mediated diseases. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of IgE-mediated diseases.

Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

Growing community of inventors

Potomac, MD, United States of America

Peter Kiener